Invus Financial Advisors

Edgewise Therapeutics, founded in 2017 and based in Boulder, Colorado, is a clinical-stage biopharmaceutical company dedicated to developing precision medicine therapies for severe, rare muscle disorders. The company's core expertise lies in muscle biology and small molecule engineering, which it employs through its proprietary drug discovery platform. This platform uses custom-built systems to measure integrated muscle function, enabling the identification of small molecule therapies targeting key proteins in muscle tissue. Edgewise's pipeline focuses on addressing genetically defined muscle disorders such as Duchenne muscular dystrophy, Becker muscular dystrophy, and limb-girdle muscular dystrophies.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly for patients with mTOR pathway driver alterations, such as those involving the TSC1 or TSC2 genes. Aadi's primary aim is to create transformational therapies for patients with specific cancer types, including the ultra-rare perivascular epithelioid cell tumor (PEComa). The company addresses challenges faced by existing mTOR inhibitors, including issues related to pharmacology, drug delivery, safety, and targeting. Founded in 2011, Aadi Bioscience has positioned itself to innovate in the treatment of oncology and cardiovascular diseases.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Dorsia is a members-only restaurant booking platform with access to coveted reservations at the most in-demand restaurants.

Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies.

Call Your Mother, established in 2018, is a Washington D.C.-based restaurant chain specializing in deli and bagel cuisine. It offers a variety of products including bagels, pastries, coffee, and sandwiches, along with online ordering and catering services. The company is committed to providing excellent food, service, and a fun atmosphere for its customers.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly for patients with mTOR pathway driver alterations, such as those involving the TSC1 or TSC2 genes. Aadi's primary aim is to create transformational therapies for patients with specific cancer types, including the ultra-rare perivascular epithelioid cell tumor (PEComa). The company addresses challenges faced by existing mTOR inhibitors, including issues related to pharmacology, drug delivery, safety, and targeting. Founded in 2011, Aadi Bioscience has positioned itself to innovate in the treatment of oncology and cardiovascular diseases.

Ottimo Pharma is a biopharmaceutical company dedicated to developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that simultaneously targets two critical pathways in cancer growth: immune checkpoint inhibition and angiogenesis. By addressing these pathways concurrently, Ottimo Pharma aims to improve treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Tasca is a biotechnology company that offers small molecule drugs for hard-to-treat oncology indications.

PrognomiQ is a technology company specializing in transforming the early detection and treatment of complex diseases like cancer. It generates comprehensive proteomic, genomic, and metabolomic data to provide insights into these conditions, aiming to enhance patient outcomes. The company's innovative approach involves developing advanced test products that improve understanding and management of health issues by integrating diverse health data types.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for conditions with significant unmet needs. The company's approach emphasizes the creation of therapies that offer oral bioavailability, which allows for effective drug delivery while minimizing first-pass metabolism and reducing the risk of hepatotoxicity and other side effects. By addressing these critical challenges, Seaport Therapeutics aims to improve the quality of life for patients living with neuropsychiatric disorders.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

City Therapeutics is a biopharmaceutical company specializing in the development of next-generation small-interfering RNAs (siRNAs) to enhance RNA interference (RNAi) therapies. The company's pipeline comprises innovative RNAi therapeutics targeting diverse disease indications. City Therapeutics aims to improve and expand RNAi technology to achieve better patient outcomes, led by a team of experienced scientists and industry professionals committed to advancing the field of RNA interference.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Egetis Therapeutics AB is a pharmaceutical drug development company based in Stockholm, Sweden, that specializes in late-stage projects targeting serious rare diseases with significant unmet medical needs, particularly within the orphan drug segment. The company is actively developing several innovative therapies, including PledOx, which is undergoing Phase III clinical trials to protect patients from chemotherapy-induced nerve damage while preserving the anticancer effects. Additionally, Egetis is working on Emcitate, a treatment for MCT8 deficiency, a rare genetic condition affecting thyroid hormone signaling, and Aladote, which aims to mitigate the risk of acute liver injury from acetaminophen poisoning. Founded in 2006, Egetis Therapeutics was previously known as PledPharma AB until its name change in December 2020.

KNIME is a provider of open-source data science platforms that facilitate collaborative analysis and automation of workflows. Its software enables users to create, deploy, and share analytical models, while offering integrated tools for data access, mining, statistics, visualization, and reporting. This empowers organizations to make data-driven decisions efficiently and innovatively.

Rapido is a Bengaluru-based company established in 2015 that operates a bike taxi booking platform focused on providing affordable intra-city travel and last-mile connectivity. Through its mobile application, users can book two-wheeler rides, promoting a more efficient commuting experience. The platform aims to connect individuals traveling in similar directions, thereby reducing the number of vehicles on the road and contributing to decreased traffic congestion, carbon emissions, and air pollution. By offering a viable alternative to vehicle ownership, Rapido enhances accessibility and encourages the sharing economy, making urban commuting not only more fun but also more sustainable.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Founded in 2017 and originally named Llama Therapeutics, the company aims to address significant unmet medical needs in neuropsychiatry, neurodegeneration, and neuroinflammation. Autobahn's lead candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential adjunctive treatment for multiple sclerosis, adrenomyeloneuropathy, major depressive disorder, and bipolar disorder depression. The company employs a brain-targeting chemistry platform that allows for precise tuning of CNS exposure while pursuing validated clinical and biological targets, guided by biomarkers, to unlock new therapeutic opportunities.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Cartesian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in the United States that specializes in developing innovative cell and gene immunotherapies for the treatment of cancer and autoimmune diseases. The company focuses on chimeric antigen receptor therapies to address multiple myeloma and other forms of cancer. Cartesian Therapeutics employs its proprietary ImmTOR immune tolerance platform, which aims to foster antigen-specific immunity while reducing unwanted immune responses. This approach utilizes a manufacturing platform to introduce mRNA molecules into cells, enhancing their functionality without the risk of integration into the cell's genetic material, as mRNA naturally degrades over time.

Klarity is a technology company that specializes in automating the contract review process for organizations. Founded by Andrew Antos, a Harvard-trained lawyer, and Nischal Nadhamuni, an MIT Computer Science graduate, Klarity's software streamlines the review of customer contracts in accordance with ASC 606 and IFRS 15 standards. The platform employs machine learning and artificial intelligence to analyze contracts for clauses that may impact revenue, while also maintaining compliance with legal policies. Klarity organizes relevant documents—such as Master Service Agreements, Order Forms, Revenue Recognition schedules, and invoices—into a single record, facilitating easier access and management. By standardizing the review process with checklists and providing annotated documents, Klarity helps organizations expedite their contract reviews and enhance compliance efficiency.

Bright Peak Therapeutics is a biotechnology company focused on developing a range of immunotherapies aimed at treating cancer and autoimmune diseases. The company specializes in creating immuno-cytokines that possess pharmacological properties enabling tissue and cell-specific targeting of cytokine payloads. This innovative approach is designed to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging its expertise in cytokine therapeutics, Bright Peak aims to advance the field of immunotherapy and provide effective solutions for challenging medical conditions.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Alterome Therapeutics is a biotechnology company focused on precision oncology, specializing in the development of alteration-specific therapeutics aimed at treating cancer. By targeting high-value and validated oncogenic drivers, Alterome seeks to create innovative biopharmaceutical therapies that offer hope to individuals affected by cancer. The company's approach is centered on discovering and developing precise treatments that cater to the unique genetic alterations present in different cancer types, thereby enhancing the effectiveness of cancer therapies for healthcare providers and patients alike.

Pi Health is a technology company specializing in streamlining oncology clinical trials. It offers a global, secure, and compliant platform that integrates various systems, enabling life sciences companies to identify suitable trial sites, manage them efficiently, and accelerate the development of lifesaving medicines. This, in turn, enhances patient access to cancer care and research, and facilitates the inclusion of diverse patient populations in clinical trials.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat various human diseases. The company's portfolio includes several drug candidates in different stages of clinical trials. LX9211 is an orally-delivered small molecule being tested for neuropathic pain treatment. Sotagliflozin, another orally-delivered small molecule, is under investigation for heart failure and type 1 diabetes. Additionally, the company has developed LX4211 for type 2 diabetes, LX2931 for rheumatoid arthritis and other autoimmune diseases, and LX7101 for glaucoma treatment. Lexicon Pharmaceuticals has established collaborations with several pharmaceutical companies, including Bristol-Myers Squibb, Genentech, Organon, Takeda, Symphony Icon, Taconic Farms, and Nuevolution A/S.

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company headquartered in San Diego, California, dedicated to the discovery, development, and commercialization of innovative therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist currently undergoing Phase I clinical trials aimed at treating acromegaly and neuroendocrine tumors. In addition to paltusotine, Crinetics is developing several other therapeutics, including CRN01941, an oral selective nonpeptide sst2 biased agonist for neuroendocrine tumors, and an oral somatostatin type 5 receptor agonist for congenital hyperinsulinism. The company is also working on an oral adrenocorticotrophic hormone antagonist for conditions such as Cushing’s syndrome and congenital adrenal hyperplasia. Founded in 2008, Crinetics Pharmaceuticals is focused on leveraging its internal discovery efforts to create effective treatments while utilizing hormonal biomarker endpoints to enhance the efficiency and cost-effectiveness of its clinical studies.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Health Data Analytics Institute, LLC is a Massachusetts-based company founded in 2016 that focuses on developing an advanced analytics and predictive platform aimed at measuring clinical risks. Utilizing artificial intelligence, the company leverages electronic health records and Blue Button data to deliver real-time assessments and on-demand analytics related to patient risks, including mortality, readmission, complications, and disease progression. The platform is designed to transform complex health data into actionable insights that can enhance patient care and inform clinical decision-making. By offering calibrated analytical models through its API, Health Data Analytics Institute caters to a diverse clientele, including healthcare organizations, researchers, practitioners, and data scientists, facilitating the development of targeted treatments and effective health services across various populations.

PayJoy Inc. is a consumer financing company based in San Francisco, California, founded in 2015. The firm specializes in providing smartphone-enabled financing solutions, primarily targeting underbanked individuals in emerging markets. By leveraging mobile security technology, PayJoy allows customers to select a smartphone, make an initial deposit, and choose a flexible payment plan. The financed smartphone serves as collateral, unlocking its full functionality once the purchase is complete. PayJoy's mission is to enhance access to credit for underserved populations, helping them navigate financial challenges and improve their economic standing. The company has successfully reached over 10 million customers across various countries, including Mexico, Brazil, Colombia, and South Africa, and continues to show solid profitability and growth.

Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, focused on developing adeno-associated virus (AAV)-based therapies for monogenic diseases of the central nervous system (CNS). Founded in 2019, the company aims to create curative treatments for severe and life-threatening conditions. Its pipeline includes several product candidates, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha collaborates with The University of Texas Southwestern Medical Center to enhance its development and commercialization efforts, leveraging expertise in gene therapy to advance its mission of eradicating monogenic CNS diseases.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Established in 2019, the company specializes in genetic medicine by utilizing a proprietary platform that employs endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in RNA transcripts. This innovative approach aims to restore the production of functional proteins, offering potential treatments for a variety of diseases, including those affecting genetic, cardiometabolic, complement-mediated, and central nervous system areas. ADARx Pharmaceuticals is dedicated to developing life-saving therapeutics that address genetic mutations and provide solutions for conditions that are currently considered incurable.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Septerna is a biotechnology company focused on the discovery and development of novel small-molecule medicines that target G protein-coupled receptors (GPCRs). The company aims to improve patient outcomes by leveraging advanced drug discovery technologies, including innovative screening methods and structure-based drug design. Septerna utilizes its proprietary Native Complex platform to facilitate industrial-scale drug discovery, enabling researchers to identify effective treatments for a diverse array of diseases. Through its commitment to combining cutting-edge technology with a focus on GPCR targets, Septerna seeks to advance the field of medicine and enhance the quality of life for patients.

Convergent Therapeutics is a clinical-stage biotechnology company specializing in the development of radiopharmaceutical therapies for prostate cancer. The company's lead product, CONV 01-α, is a monoclonal antibody conjugated with the radioactive alpha particle emitter 225Ac, designed to bind specifically to the prostate-specific membrane antigen (PSMA). This innovative therapy allows for the internalization of the radioactive payload directly into prostate cancer cells, enhancing treatment efficacy. Developed through proprietary technology by Dr. Neil Bander at Weill Cornell Medicine, CONV 01-α is protected by multiple U.S. and foreign patents. If it receives FDA approval, it will become the first antibody to target a radioisotope for prostate cancer treatment and the first drug to utilize 225Ac in this context. Convergent Therapeutics aims to leverage its therapeutic platform to explore targeted combination strategies against validated and novel cancer antigens, ultimately enhancing treatment options for patients.

Orbital Therapeutics is a biotechnology company dedicated to advancing global health through innovative RNA-based medicines. It develops a proprietary platform that combines cutting-edge RNA technology, delivery techniques, data analytics, and automation to create an extensive portfolio of transformative therapies across various disease areas such as vaccines, immunomodulation, protein replacement, and regenerative medicine. The company's mission is to provide patients with novel treatment options for diseases previously considered untreatable or challenging to manage.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Flare Therapeutics is a biotechnology company dedicated to developing small molecule medicines through a novel approach to understanding transcription factors. By identifying 'switch sites,' which are druggable regions crucial for regulating transcription factors, Flare aims to target mutations that lead to various diseases. The company has rapidly advanced its drug discovery efforts, creating an emerging pipeline of programs initially focused on precision oncology. Additionally, Flare's innovative platform holds promise for addressing conditions in neurology, rare genetic disorders, immunology, and inflammation, ultimately enabling medical professionals to transform treatment strategies for patients.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative gene therapies utilizing its proprietary Anellovector platform. This platform, based on the human commensal virome, addresses several limitations of existing gene therapies, including restricted access to diverse tissues, challenges in redosing, risks of genomic integration, and issues with tolerability. Founded in 2017 and previously known as VL46, Inc., Ring Therapeutics aims to expand the applications of gene therapy beyond traditional gene replacement. By enabling a broader range of therapeutic modalities and mechanisms, the company seeks to treat a variety of previously inaccessible diseases, including genetic disorders, ophthalmology, oncology, and metabolic conditions.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Canada, specializing in the development of next-generation radiopharmaceuticals as precision medicines for challenging cancers. The company leverages its Targeted Alpha Therapies platform and proprietary Fast-Clear linker technology to connect alpha particle-emitting isotopes with antibodies and other targeting molecules, enabling selective delivery of cytotoxic payloads to tumors. Its lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, Fusion is conducting preclinical studies to explore the combination of FPI-1434 with approved checkpoint inhibitors and DNA damage response inhibitors to enhance anti-tumor activity. The company is also advancing FPI-1966, aimed at treating head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014, Fusion Pharmaceuticals aims to innovate within the field of radiopharmaceuticals, transforming internalizing antibodies into effective cytotoxic drugs for improved cancer treatment outcomes.

BelliWelli is a Los Angeles-based company founded in 2020 that specializes in gut-friendly, plant-based snack bars designed for individuals with irritable bowel syndrome (IBS). The company offers a range of gluten-free, dairy-free, and low-sugar bars that are certified low-FODMAP, providing a healthy snacking option for those managing digestive sensitivities. BelliWelli's products, made with ingredients like almond butter, chia seeds, and cinnamon, aim to enhance consumer awareness of IBS while promoting digestive health through the inclusion of probiotics in their snacks.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Aravive Biologics is a clinical-stage biotechnology company based in Houston, Texas, founded in 2008. The company specializes in developing novel cancer therapeutics aimed at treating various types of malignancies, including solid tumors and hematologic cancers. Aravive's approach involves targeting critical survival pathways, with a key therapeutic candidate designed to act as a decoy that binds to the GAS6 pathway with high affinity, thereby preventing the activation of the AXL signaling pathway. This strategy is intended to inhibit cancer cell growth and survival.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Salt Lake City, Utah, that focuses on revolutionizing drug discovery through the integration of advanced technologies such as artificial intelligence, automation, and bioinformatics. Founded in 2013, the company has developed a comprehensive drug discovery platform that includes various tools and software, such as ReChem for chemical compound design, ReScreen for managing complex experimental workflows, and RePredict for modeling drug relationships using machine learning. These innovations enable Recursion to generate extensive biological and chemical datasets, facilitating the exploration of foundational biology and accelerating the development of new therapeutic solutions. Through its unique approach, Recursion aims to significantly enhance patient outcomes and streamline the drug discovery process.

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Founded in 2017 and originally named Llama Therapeutics, the company aims to address significant unmet medical needs in neuropsychiatry, neurodegeneration, and neuroinflammation. Autobahn's lead candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential adjunctive treatment for multiple sclerosis, adrenomyeloneuropathy, major depressive disorder, and bipolar disorder depression. The company employs a brain-targeting chemistry platform that allows for precise tuning of CNS exposure while pursuing validated clinical and biological targets, guided by biomarkers, to unlock new therapeutic opportunities.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

Sironax is a clinical-stage biotechnology company based in Beijing, China, founded in 2017. The company specializes in developing innovative products and treatments targeting age-related degenerative diseases. Sironax focuses on key mechanisms such as regulated cell death, neuroprotective pathways, and neuroinflammation, conducting research on apoptosis and other cell death pathways. By advancing pharmaceutical solutions for inflammatory and neurodegenerative diseases, Sironax aims to transform the treatment landscape and enhance the quality of life for millions of patients and their families globally.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat various human diseases. The company's portfolio includes several drug candidates in different stages of clinical trials. LX9211 is an orally-delivered small molecule being tested for neuropathic pain treatment. Sotagliflozin, another orally-delivered small molecule, is under investigation for heart failure and type 1 diabetes. Additionally, the company has developed LX4211 for type 2 diabetes, LX2931 for rheumatoid arthritis and other autoimmune diseases, and LX7101 for glaucoma treatment. Lexicon Pharmaceuticals has established collaborations with several pharmaceutical companies, including Bristol-Myers Squibb, Genentech, Organon, Takeda, Symphony Icon, Taconic Farms, and Nuevolution A/S.

AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. The company's lead product, Viralym-M, targets multiple viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Additionally, AlloVir is advancing several product candidates through preclinical and clinical stages, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. The company, originally founded in 2013 as ViraCyte, Inc., rebranded to AlloVir in May 2019 and is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

Scholar Rock, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of biologic therapies that selectively target dysregulated growth factors within disease microenvironments. The company's innovative approach focuses on modulating supracellular activation to address serious diseases, including fibrosis, musculoskeletal disorders, immuno-oncology, and autoimmune diseases. Scholar Rock's lead product candidate, SRK-015, is a first-in-class inhibitor designed to target the activation of the growth factor myostatin in skeletal muscle, specifically for the treatment of spinal muscular atrophy. The company is advancing this candidate through clinical development while also leveraging its proprietary platform to create a pipeline of additional product candidates aimed at transforming treatment for various serious conditions, including other neuromuscular disorders, cancer, and anemia.

HappyVore, previously known as Les Nouveaux Fermiers, is a Paris-based company established in 2020 that specializes in manufacturing and selling plant-based meat products. The company aims to reinvent traditional meat recipes using natural and local plant ingredients, ensuring that its offerings are free from genetically modified organisms. HappyVore's products are designed to appeal to both restaurants and consumers, promoting a healthier and more sustainable alternative to conventional meat. Notably, their plant-based options generate significantly lower carbon emissions and require substantially less water than traditional meat production, aligning with the company’s commitment to environmental impact and healthier eating. Through its online sales platform, HappyVore seeks to encourage a shift towards a vegan diet while maintaining a focus on taste and quality.

ImCheck Therapeutics is a biopharmaceutical company based in Marseille, France, that specializes in developing immunotherapeutics aimed at addressing severe unmet medical needs, particularly in the field of immuno-oncology. Founded in 2015, the company focuses on designing and developing immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules. These innovative therapies engage γ9δ2 T cells, a specific type of immune cell, to effectively treat various cancers, including breast, gastric, and ovarian cancers, as well as other solid tumors. Through its advanced research and development efforts, ImCheck Therapeutics seeks to provide next-generation immunotherapeutics for patients suffering from immune-related diseases.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, a targeted cancer therapy using gene-engineered allogeneic CAR-NK cells designed to eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A for treating hepatocellular carcinoma.

MoMa Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company specializes in discovering precision medicines by targeting the molecular machines that are fundamental to human disease. Formerly known as ATPases NewCo, Inc., MoMa Therapeutics utilizes a unique platform that leverages the shared characteristics of ATPase enzymes, including their large-scale conformational changes and energy-driven mechanics. By integrating advances in structural biology and small-molecule drug discovery, MoMa Therapeutics aims to develop therapies targeting this previously challenging class of enzymes, thereby advancing the field of precision medicine.

Zero Motorcycles manufactures and supplies electric motorcycles, offering street, dirt, and dual-sport models along with accessories and apparel. The company is dedicated to revolutionizing the motorcycle industry by combining traditional design elements with advanced technology, resulting in high-performance, environmentally friendly vehicles. Zero Motorcycles was founded in 2006 and is headquartered in Scotts Valley, California, with an additional office in Noord-Scharwoude, the Netherlands. The company sells its products through dealers and online, and has a strategic partnership with Polaris Inc.

Onxeo is a clinical-stage biotechnology company based in Paris, France, focused on developing innovative oncology drugs that target tumor DNA repair mechanisms. The company offers Beleodaq, a treatment for relapsed or refractory peripheral T-cell lymphoma, and is advancing several other candidates, including Livatag, a nanoparticle formulation of doxorubicin currently in Phase III trials for primary liver cancer. Validive, a buccal tablet for preventing and treating severe oral mucositis in head and neck cancer patients, has completed Phase II trials. Additionally, Onxeo is developing AsiDNA, which is undergoing Phase 1 trials for metastatic melanoma, and OX401, which is in preclinical development for DNA damage response and immuno-oncology applications. The company has established partnerships with Spectrum Pharmaceuticals for Beleodaq, Monopar Therapeutics for Validive, and Gustave Roussy for the clinical trials of AsiDNA in relapsed ovarian cancer. Onxeo, previously known as BioAlliance Pharma, was founded in 1997 and has a commitment to advancing oncology treatments worldwide.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

PrognomiQ is a technology company specializing in transforming the early detection and treatment of complex diseases like cancer. It generates comprehensive proteomic, genomic, and metabolomic data to provide insights into these conditions, aiming to enhance patient outcomes. The company's innovative approach involves developing advanced test products that improve understanding and management of health issues by integrating diverse health data types.

Septerna is a biotechnology company focused on the discovery and development of novel small-molecule medicines that target G protein-coupled receptors (GPCRs). The company aims to improve patient outcomes by leveraging advanced drug discovery technologies, including innovative screening methods and structure-based drug design. Septerna utilizes its proprietary Native Complex platform to facilitate industrial-scale drug discovery, enabling researchers to identify effective treatments for a diverse array of diseases. Through its commitment to combining cutting-edge technology with a focus on GPCR targets, Septerna seeks to advance the field of medicine and enhance the quality of life for patients.

Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Jumbotail Technologies Pvt. Ltd., established in 2015 and headquartered in Bengaluru, India, operates an online marketplace that streamlines food and grocery shopping for wholesalers. The company connects tens of thousands of Kirana stores with brands and traders, offering a wide range of high-quality products. Jumbotail provides a suite of services including supply chain logistics, a mobile ordering app, point-of-sale integration, and credit solutions for shop owners. Its mission is to organize India's food and grocery ecosystem using technology, data science, and design, targeting the next billion people with unique needs. The company is led by a strong team with experience from prominent organizations like Amazon, Flipkart, and BCG.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

ezCater, Inc. is an online catering marketplace that facilitates food ordering for both small startups and large corporations. Founded in 2007 and headquartered in Boston, Massachusetts, with an additional office in Denver, the company connects businesses with local caterers and restaurants across the nation. ezCater offers a platform that allows users to easily find and order food for meetings and events, utilizing features that filter caterers by food type, budget, and other criteria. The company's solutions include ezManage, a catering management platform, and ezOrdering, which enables restaurants to accept catering orders directly through their websites. By streamlining the catering process, ezCater helps clients save time and efficiently select suitable catering options.

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Laronde is a biotechnology company that specializes in developing an eRNA-based therapeutic platform designed to express a variety of proteins within the body. Founded in 2017 by Flagship Labs, Laronde's innovative Endless RNA technology is engineered to be persistent and non-immunogenic, allowing for repeat dosing and offering flexibility in both formulation and delivery. This platform aims to enhance the predictability and efficacy of new medicines, facilitating the development of therapeutics that can address a wide range of diseases. As Laronde continues to scale its operations, it focuses on advancing multiple programs simultaneously, positioning itself as a key player in the future of medicine.

Vigil Neuroscience Inc is a therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by targeting microglia, the brain's immune cells. The company aims to restore the vigilance of these cells to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 clinical studies, while also working on VG-3927, an orally available small molecule TREM2 agonist. These efforts are part of a broader strategy to build a robust pipeline of therapies supported by the understanding of microglia biology as a critical therapeutic pathway. Vigil's clinical candidate, iluzanebart, is currently undergoing a Phase 2 proof-of-concept trial in patients with ALSP, marking a significant step in the company's commitment to precision-based neuroscience drug development.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative gene therapies utilizing its proprietary Anellovector platform. This platform, based on the human commensal virome, addresses several limitations of existing gene therapies, including restricted access to diverse tissues, challenges in redosing, risks of genomic integration, and issues with tolerability. Founded in 2017 and previously known as VL46, Inc., Ring Therapeutics aims to expand the applications of gene therapy beyond traditional gene replacement. By enabling a broader range of therapeutic modalities and mechanisms, the company seeks to treat a variety of previously inaccessible diseases, including genetic disorders, ophthalmology, oncology, and metabolic conditions.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.